INS and Hypoglycemia: On the other hand, in type 2 diabetes under insulin and/or hypoglycemic oral treatment, the use of a CGM device reduces HbA1c, but not the rates of hypoglycemia 108, while in gestational diabetes these devices help to achieve a better daytime glucose profile, providing an improvement in both maternal and neonatal outcomes 108, 181.